Skip to main content
PepStack
Blutwerte · Marker

Aldosteron

Aldosterone · Mineralocorticoid

Hormone — StressachseZeitabhängig
Einheit:
nmol/L
Abbreviation
Aldo

Aldosterone quantifies the level of this mineralocorticoid hormone in the blood, reflecting adrenal gland function and RAAS activity.

Reference Ranges

Reference
0.10.6nmol/L
0.1
0.6
LowNormalHigh
Reference
Unit · nmol/L

Levels can vary based on posture, time of day, and sodium intake.

Overview

Übersicht

Aldosterone (Aldo), a mineralocorticoid hormone produced by the adrenal glands, plays a crucial role in regulating sodium and potassium balance, as well as blood pressure. It acts primarily on the distal tubules and collecting ducts of the nephron, promoting sodium reabsorption and potassium excretion, thus influencing fluid balance and blood pressure. Researchers have found that aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which is activated in response to low blood volume or pressure. Clinically, aldosterone is significant in diagnosing conditions like primary aldosteronism, characterized by excessive aldosterone production leading to hypertension and increased cardiovascular risk. Elevated aldosterone levels are also associated with heart failure and chronic kidney disease, contributing to inflammation and fibrosis. For athletes and biohackers, aldosterone's role in fluid and electrolyte balance is critical, as it can affect performance and recovery. However, researchers observed that factors such as time of day, posture, and dietary sodium intake can influence aldosterone levels, making standardized testing conditions important for accurate assessment. Additionally, aldosterone levels can be affected by medications such as mineralocorticoid receptor antagonists, which are used therapeutically in conditions like heart failure and hypertension.

Klinische Bedeutung

Elevated aldosterone levels can indicate primary aldosteronism, heart failure, or chronic kidney disease, while low levels may suggest adrenal insufficiency or hypoadrenocorticism. Both extremes can lead to significant electrolyte imbalances and blood pressure issues.

Dynamics

Trend Interpretation

Rising Values

Progressively rising aldosterone levels may indicate worsening primary aldosteronism or heart failure. Re-test in 4 weeks if levels are outside the optimal range.

Falling Values

Falling levels could suggest improving adrenal function or effective treatment of primary aldosteronism.

Re-test Interval

4 weeks if outside optimal range

Etiology

Causes — High & Low

Cause

Elevated Levels

  • Primary aldosteronism
  • Chronic heart failure
  • Chronic kidney disease
  • Renal artery stenosis
  • Cirrhosis
Cause

Low Levels

  • Addison's disease
  • Hypopituitarism
  • Congenital adrenal hyperplasia
  • Critical illness
  • Long-term heparin therapy
Protocol

How to Optimize

Lever

Lifestyle

  • Manage stress levels
  • Regular physical activity
  • Monitor blood pressure regularly
Lever

Nutrition

  • Reduce sodium intake
  • Increase potassium-rich foods
  • Maintain adequate hydration

Note:

Consult a healthcare provider before making significant dietary or lifestyle changes, especially if on medication.

Testing Guidelines

Fasting Not Required
🕐Time-Sensitive

Aldosterone levels are typically higher in the morning; testing should be consistent in timing.

Testing Frequency

Annually for those with hypertension or adrenal disorders.

Interfering Factors

  • Posture changes
  • Dietary sodium intake
  • Use of diuretics

Related Peptides & Hormones

Cortisol

Correlated with

hormone

Open Research Questions

Current research suggests that the reference ranges for aldosterone levels and the optimal targets for treatment in conditions like primary aldosteronism remain poorly defined, leading to potential underdiagnosis. Researchers have not yet established the long-term effects of emerging therapies, such as aldosterone synthase inhibitors, on cardiovascular and renal outcomes. Additionally, clinical questions remain unanswered regarding the interplay between aldosterone levels and co-secretion of cortisol in patients with hypertension and the implications for treatment strategies.

20 Research Publications

493

Total Citations

2

Human/RCT

3.8

Avg. Influence

2024

Latest

Sort
Filter
#01

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Meta-AnalysisInfluence12.0
179
Researchers conducted a meta-analysis to assess the impact of SGLT2 inhibitors on hyperkalemia in patients with type 2 diabetes. They found that these inhibitors reduce the risk of serious hyperkalemia without increasing the risk of hypokalemia.
View on PubMed
#02

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.

In VitroInfluence6.0
65
Researchers evaluated the safety and pharmacokinetics of baxdrostat, an aldosterone synthase inhibitor, in healthy volunteers. They found that baxdrostat significantly reduced plasma aldosterone levels without affecting cortisol levels. The study concluded that baxdrostat was safe and well tolerated, supporting its potential use in conditions associated with elevated aldosterone.
View on PubMed
#03

Canine hypoadrenocorticism: pathogenesis, diagnosis, and treatment.

ReviewInfluence3.0
56
This study examined hypoadrenocorticism in dogs, a condition caused by decreased hormone production from the adrenal glands. Researchers found that definitive diagnosis requires specific hormone testing, including aldosterone levels, and noted that the prognosis is good with appropriate supplementation.
View on PubMed
#04

Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.

ReviewInfluence1.0
56
Researchers explored the clinical significance of hyperkalemia associated with renin-angiotensin-aldosterone system inhibitors, noting it as a common adverse effect. The study emphasized the need for effective management strategies to mitigate hyperkalemia while allowing continued use of these beneficial medications.
View on PubMed
#05

A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.

ReviewInfluence1.0
30
Researchers reviewed finerenone, a new non-steroidal mineralocorticoid receptor antagonist, and its potential benefits in treating cardiovascular and renal diseases. They found that finerenone shows promise in improving outcomes for patients with type 2 diabetes and chronic kidney disease.
View on PubMed
#06

Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.

ReviewInfluence1.0
26
Researchers reviewed the role of aldosterone in cardio-kidney diseases, highlighting its harmful effects on heart and kidney function. They found that mineralocorticoid receptor antagonists can mitigate these effects, but further studies are needed to clarify their clinical implications.
View on PubMed
#07

Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen.

ReviewInfluence1.0
23
Researchers reviewed the pharmacological effects of drospirenone, a progestin with anti-mineralocorticoid activity. They found that drospirenone formulations can positively influence metabolic parameters and cardiovascular health, although the clinical relevance of these effects requires further investigation.
View on PubMed
#08

Posaconazole-Induced Pseudohyperaldosteronism.

Case Report
20
This case report described a woman who developed symptoms of heart failure and hypertension while on posaconazole treatment. Researchers found low renin and aldosterone levels, suggesting a mechanism of apparent mineralocorticoid excess due to drug interaction.
View on PubMed
#09

Diagnosis of canine spontaneous hypoadrenocorticism.

ReviewInfluence5.0
19
This study focused on diagnosing spontaneous hypoadrenocorticism in dogs, characterized by reduced hormone production. Researchers noted that affected dogs often present with vague symptoms before a crisis occurs, emphasizing the need for proper classification and laboratory evaluation.
View on PubMed
#10

Real-world outcomes of finerenone in primary aldosteronism.

Case Report
11
This real-world study evaluated the effects of switching primary aldosteronism patients from eplerenone to finerenone. Researchers observed unchanged blood pressure but a decrease in the proportion of patients achieving normal biochemical responses, indicating the need for further research.
View on PubMed

Clinical Trials (1)

1

Total Trials

20

Total Enrolled

Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism

NCT06478875Phase 2NOT_YET_RECRUITING
Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

20

Started

2024

Primary outcome

relevant biomarkers strongly associated with primary lateralized hyperaldosteronism

Primary Aldosteronism

Publication Trend

Research publications about Aldosteron over time

9total
1
'14
1
'18
2
'22
1
'23
1
'24
2
'25
1
'26

Track your bloodwork in PepStack

Log lab results, track trends and optimize your biomarkers over time.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer